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The meeting was organized in the light of the impetus from health
authorities to push ahead with implementation of the Calman–
Hine Report in breast cancer services. This is an appropriate time
to review progress in implementation so far and to assess
problems.
Background to Calman–Hine and guidelines for breast
cancer management – Robert Haward (University of
Leeds, UK)
The rationale for Calman–Hine (C–H) (Department of Health,
1995) and its equivalents in Scotland and Northern Ireland, was to
eliminate significant variations in cancer management within the
UK – variations which have proved very persistent. The nature and
extent of this variation can be inferred from cancer registry data,
from audits, and from other observational studies, rather than from
randomized trial evidence. There has been a public perception of
significant geographical differences in access to cancer services, in
diagnostic and treatment approaches, and in communications. This
contributed to the political pressure for something to be done.
The Expert Advisory Group on Cancer (EAGC) which
produced C–H reviewed the evidence in a number of key areas.
They concluded that there was a real problem, that there were
strong grounds for systematic specialization in the delivery of
cancer care, and that multidisciplinary teams were an important
factor in improving the service. The evidence for the effectiveness
of a network system of care – the unit-centre model, linked to
primary care – is rather weaker, but there is evidence that collabo-
ration involving people in different institutions can lead to better
and more consistent care.
The aim of the strategy implicit in C–H’s recommendations was
the improvement of local delivery of services, using documented,
audited and monitored procedures, and ensuring proper linkage
between the different aspects of delivery. C–H saw cancer services
commissioning as a key potential influence on the implementation
of the necessary changes. Other necessary elements to support
implementation were guidelines and the systematic recording of
agreed data. Guidelines can be either clinical, like those from
BASO (British Association of Surgical Oncology, 1995) or about
service delivery – which led to the production of the national COG
(Cancer Guidance Sub-Group of the Clinical Outcomes Group)
guidance. Initiatives to encourage the use of systems for collection
of data are now beginning to come through e.g. the Royal College
of Pathologists’ minimum reporting standards, and minimum
datasets and associated databases defined by various national
associations such as BASO.
The first national COG guidance related to services for the
management of breast cancer (COG, 1996). A great deal of
activity has followed in relation to setting up the right structures
for breast services in cancer units and centres, although the precise
process has varied markedly across the country. The most signifi-
cant recommendations in both the clinical guidelines and national
guidance were for the constitution of specialist breast teams in
cancer units and centres. Much effort has been applied throughout
the UK to constitute such teams and to get them to work effec-
tively, with all breast patients referred to them. The concept of
triple assessment has also been widely embraced. Less consistent
progress has been made in areas such as communication and
monitoring outcomes.
The great majority of symptomatic breast patients are now
seeing designated surgeons. Most surgeons are beginning to work
in teams with appropriate colleagues, despite practical restrictions.
The quality of team-working within these specialist teams varies
considerably, however. The variations can partly be explained by
logistical difficulties and are sometimes a result of the shortage of
trained people to fill vacant posts. There are also problems in
establishing meaningful communication between specialist teams
in hospitals and primary care. More rigorous quality assurance and
more peer-review visiting would be beneficial.
Considerable change and a lot of progress has been made over
the last decade since breast screening was generally introduced.
It has been followed by C–H, a framework for all cancer services,
and by the detailed COG guidance. While this broke new ground
in seeking to standardize the way breast cancer services are
delivered across the NHS, there is still a long way to go.
Review of radiology/screening – Robin Wilson (City
Hospital, Nottingham, UK)
The introduction of the National Breast Screening Programme
(NHSBSP) arguably provided the driving force behind all the
measures under discussion at the meeting. Breast cancer care
is viewed as the model for care in other kinds of cancer. The
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and is fundamental to accurate diagnosis (Teh et al, 1998; Blamey,
1998), preoperative staging of cancer, surveillance after treatment,
and restaging for recurrent or metastatic disease.
The NHSBSP has demonstrated the value to patients of inte-
grating imaging into the primary diagnostic process. The radiolo-
gist needs to attend new-referral clinics alongside the surgeon,
providing instant reporting of mammograms and carrying out
ultrasound scans and image-guided biopsy. In the assessment of
patients with breast cancer, the mammogram and ultrasound
features are fundamental in determining the disease extent and
whether conservation surgery is feasible. During initial diagnosis
and treatment, the radiologist must also participate in the multidis-
ciplinary clinical meetings along with the surgeon, pathologist and
oncologist to ensure that the most appropriate management deci-
sions are made for each patient. Some 40 standards have been
published within the NHSBSP, and a few more are in the pipeline.
The Royal College of Radiologists, Royal College of Radiologists
Breast Group, BASO, and the British Breast Group have all, over
the last 5 years, produced their own guidelines.
Radiologists involved in the breast-screening programme have
all the skills required for symptomatic breast imaging, and it is
only sensible that the same radiologists should also support symp-
tomatic breast radiology. However, the extension of the radiolo-
gist’s role in symptomatic breast care is considerably increasing
the demand for specialist radiology time. This is on top of
increasing demands within the NHSBSP and compounded by
changes in practice in breast diagnosis, with radiologists now
carrying out needle biopsies of breast abnormalities, under image
guidance, even for palpable lesions. Radiology is now the rate-
limiting step that determines how fast patients are seen in the
clinic. Features of lumps can now be distinguished which go
beyond the solid/cystic differentiation to which ultrasound has
traditionally been restricted. Tumours can be diagnosed when they
are much smaller than was previously possible. High-frequency
ultrasound is now essential in breast cancer diagnosis. Doppler
allows assessment of the vascularity of the tumour. Doppler
contrast, and harmonics, allow still more sophisticated investiga-
tions. As regards biopsy techniques, fine-needle aspiration (FNA)
results are disappointing. This year, less than half of screening
programmes have reached the target of 70% of cancers diagnosed
preoperatively (Blanks R, personal communication). Core biopsy
is supplanting it. Using core biopsy under image guidance, it
should be possible to diagnose up to 95% of cancers preopera-
tively. Ultrasound-guided vacuum biopsy is expensive but highly
accurate (Parker et al, 1996).
In many parts of the UK there is a shortage of radiologists
specializing in breast imaging. The pressures of the NHSBSP
quality-assurance programme have reduced the enthusiasm of
radiologists in training to consider specialization in breast imaging
– radiology is currently the only breast care specialty whose prac-
titioners require to be individually peer reviewed. Twenty percent
of breast posts advertised last year are still vacant. Breast radiolo-
gists are bearing the brunt of the heightened public awareness of,
and tendency to pursue, litigation in relation to cancer screening
programmes. According to a report published in 1998, 28% of
respondents were, at the time of survey, involved in some kind of
medico-legal action citing delayed diagnosis. Also, 94% were
experiencing an increased workload, and 83% believed that stan-
dards had dropped as a result. Morale was found to be low, and
42% were seriously considering leaving (Field, 1998). To help
alleviate the manpower shortage, a working party set up by the
Chief Medical Officer has proposed that non-radiographers be
deployed to take films, while radiographers will read them.
Despite this, there will need to be a significant expansion in
numbers of breast radiologists, and considerable investment in
equipment in the clinic, if the expertise required for quality breast
cancer diagnosis and treatment is to be provided.
Role of clinical oncologist in guideline development –
lan Kunkler (Western General Hospital, Edinburgh, UK)
The clinical oncologist is involved in the delivery of radiotherapy
and cytotoxic therapy for breast cancer and forms part of a multi-
disciplinary team including breast surgeons, medical oncologists,
radiologists, pathologists, general practitioners, cancer nurses and
radiographers. It is envisaged that national guidelines such as
those drawn up by the Scottish Intercollegiate Guidelines Network
(SIGN, 1998) and the Royal College of Radiologists Clinical
Oncology Information Network (COIN, in preparation), should
form the basis for the development of locally based guidelines in
cancer centres and cancer units. Most clinical oncologists under-
take the non-surgical management of breast cancer in both cancer
units and cancer centres. They are therefore well placed to ensure
that the local guidelines in cancer centres and cancer units, devel-
oped from such national guidelines, are consistent with one
another.
In developing guidelines the clinical oncologist may contribute
to defining best practice in staging, selection of appropriate
adjuvant radiotherapy and systemic therapy following breast-
conserving therapy or mastectomy, the management of locally
advanced, recurrent and metastatic disease, and policies of
post-treatment surveillance.
The guiding principles in writing guidelines are: (a) the quality
of the evidence; (b) an interactive process by which draft guide-
lines are revised and improved by peer review; (c) avoidance of
dogma where there is insufficient evidence to support firm recom-
mendations; (d) acceptability to the professional, and (e) clarity of
expression. The highest level of evidence (level 1a) is based on a
meta-analysis of randomized controlled trials. The lowest level
(level 4) is based on expert opinion.
Assessing the quality of the evidence is not easy. For example,
the apparent lack of any improvement in survival from postopera-
tive radiotherapy in an overview of randomized trials (EBCTCG,
1995) may be at odds with a large individual trial (Overgaard et al,
1997) that does show a survival advantage.
Efforts continue to improve radiotherapy techniques, and this of
course has implications for local control and minimization of
morbidity. One problem is the uneven contour of the breast, which
gives rise to local hot-spots in radiotherapy, which may result in
local morbidity. The larger the breast, the greater its heterogeneity
(Neal et al, 1995) and the more likely a poor cosmetic result
because of imbalances in dose. New techniques for 3D planning of
the breast involve rapid acquisition of CT slices throughout the
whole substance of the breast: the path length of each slice can be
computed rapidly, and sophisticated planning algorithms can be
used to optimize the distribution of radiotherapy over the breast
(Carruthers et al, 1999). The equipment necessary is expensive,
however, and a cost–benefit judgement has to be made in
formulating relevant guidelines.
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that radiotherapy should conventionally be given after wide exci-
sion or quadrantectomy. Data from the Scottish Conservation Trial
on women under 69 years deemed suitable for conservation
therapy, who received appropriate systemic therapy based on ER
status, and who were then randomly assigned to radiotherapy or no
radiotherapy, showed a significant advantage in ipsilateral recur-
rences for the radiotherapy group (Forrest et al, 1996). Over the
whole study there was a 4 fold reduction in risk of local recurrence
for patients receiving radiotherapy. Disadvantages of breast irradi-
ation include acute and late toxicity and hospitalization for frail
patients or those living too far from the cancer centre for outpatient
treatment.
The issue of treatment of the axilla continues to arouse contro-
versy. Advice from SIGN (Chetty et al, 1998) is that, after axillary
sampling, the axilla should only be irradiated if patients are node-
positive or if they have been inadequately sampled. (However, in
the speaker’s view, the axilla should not be irradiated unless
adequately sampled, because of the risks of late morbidity.) A
recent trial at Edinburgh examined the morbidity of axillary
surgery – sample or clearance – after wide excision. Patients were
randomized to axillary node sample or level 3 clearance. Those
sampled and found node-positive received radiotherapy; those
node-negative or who received clearance, did not. The irradiated
group experienced greatest morbidity in terms of shoulder power,
followed by the clearance group. The clearance group fared worst
in terms of lymphoedema. There was no difference in survival or
axillary recurrence.
Also controversial is the issue of post-mastectomy radiotherapy.
The recent SIGN (1998) guidelines, influenced by trials from
Denmark and Canada, suggest that adjuvant post-mastectomy
radiotherapy should be given to patients at high risk of local occur-
rence, taking into account nodal positivity, lymphovascular inva-
sion, grade and size of tumour (although it is not prescriptive
about how these factors should be summated). On the basis of a
1987 overview of postoperative radiotherapy trials, which showed
increased mortality for patients undergoing post-mastectomy
irradiation, many surgeons stopped referring patients for post-
operative radiotherapy. Clinical oncologists were aware that,
within the overview, there was a wide variety of treatment tech-
niques used and that, in the early part of the period covered by the
review, the orthovoltage radiation used gave a high dose to the
heart. With modern megavoltage radiation, dosage to the heart is
relatively small. A re-analysis showed that there was a trend to a
small increase in survival in the irradiated group. A more recent,
large (n = 1708) trial (Overgaard et al, 1997) in high-risk
premenopausal women randomized post-mastectomy to adjuvant
chemotherapy alone or in conjunction with radiotherapy, and
found a survival advantage for the irradiated group (48% vs 34%
at 10 years). The clinical oncology community is currently
assessing the implications for practice.
The model of joint care: surgeons and oncologists –
Robert Mansel (University Hospital of Wales, Cardiff,
UK)
Change arising from C–H has arguably been greater for the
surgeon than for the oncologist. As has been stated earlier, the
main driving force behind C–H has been the Breast Screening
Programme. In the USA, voluntary groups have been successful in
diverting substantial amounts of money into health care from other
budgets, e.g. defence; not so in the UK. BASO has had to struggle
against opposition from general surgical groups to introduce breast
specialism. (Rescheduling of clinics has been achieved at Cardiff
only after 2
1 - 2 years of negotiation.)
Practical problems, e.g. regarding the availability of oncolo-
gists, may force departures from the ideal situation envisaged by
C–H in which, following triple assessment on a same-day or rapid-
access basis, the patient has a care plan drawn up at a multi-
disciplinary meeting attended by oncologist and surgeons. Also,
few clinics draw up treatment plans in a readily auditable form.
As regards documentation, BASO has done an enormous
amount of work: the second version of the breast database has just
been published, the second edition of the guidelines has recently
been published, and the second edition of the primary care referral
guidelines consonant with the new 2-week rule will be published
very soon. The last is a very important instrument for the future
success of C–H implementation.
At Cardiff, a weekly clinic is held with all four surgeons
together in the same clinic. (This is useful for training, since there
is always a consultant present.) For rapid communication, there is
a dedicated fax line for GPs to fax proformas. Patients are auto-
matically invited for mammograms after they reach the age of 35.
All investigations are performed on a one-stop basis, but not
results. All results are fed into a weekly multidisciplinary meeting
prior to seeing the patient to give the diagnostic results. Patients
are seen and get results within 3 days.
Recording the decisions made at the multidisciplinary meeting
allows comparison with existing guidelines and also comparison
with an ideal management for that patient’s subgroup, using
overview data. Studies looking at specialist care vs non-specialist
care in Scotland suggest that not only is the quality of the staging
better but there is lower local recurrence (by a factor of three) and
improved mortality in those patients who are looked after in a
specialist setting involving multidisciplinary working.
Outcome in terms of cosmesis needs more attention. Current
data systems don’t acquire this. Breast reconstruction still shows
marked variation in settings, outcomes and evaluation across
different locations. The BASO database in the symptomatic area
allows ready assessment of quality-of-work by individual surgeons
and can be a valuable indicator of training needs.
An important caveat needs to be registered, however. The inci-
dence of cancer among patients referred to breast clinics used to be
about 1 in 10; in a recent survey at the Cardiff breast clinic, out of
2333 referrals, there were 147 symptomatic carcinomas: 6%. This
represents one of the pressures imposed on the quality of care
which can be offered to the woman who does have cancer. The
referral guidelines take into account factors such as age, for
example. The second edition also includes a short statement about
family history. Comparing GP letters with the referral guidelines
showed that, if the guidelines had been followed, all of the symp-
tomatic cancers would have been referred, but 29% of the total
population would not have needed referral. Most patients do not
need triple assessment; they need counselling, advice, and to talk
about family history. There is a major issue here which poses a
threat, to C–H organization in the breast cancer world, since the
clinics will increasingly become populated by the ‘worried well’.
The issue of follow-up is highly contentious. COG showed that
follow-up is unnecessary, but this view is robustly opposed by
many surgeons. Are we providing a quality service? Data show
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Why not an alternative model? One could have shared primary
care and breast clinic care, which might reduce the hospital
load, leaving more time for new patients, maintain the database
by better IT from primary care to breast clinic, and have a
mammographic surveillance for follow-up.
Overall conclusions are that multidisciplinary working with
minimum standards and national guidelines should lead to better
outcomes. But we should remember that future improvements in
mortality are likely to be modest.
Chemotherapy – Mary O’Brien (Royal Marsden
Hospital, London, UK)
About a quarter of spending on anticancer drugs is for breast
cancer. The medical oncology speciality, originally largely
research-based, has developed into one providing a broad range of
opinion on cancer treatment, albeit with an emphasis on drug treat-
ment. The specialty’s evidence-based orientation has contributed
to the accumulation of a body of mature studies, many with
10–15 years follow-up.
Recent developments in chemotherapy for both early and
advanced breast cancers have important implications for the
costing and delivery of services as outlined in C–H.
A recent overview of over 50 adjuvant chemotherapy trials
involving 30 000 women established new criteria for significant
survival benefit (EBCTCG 1998a). The first key finding was that
combination chemotherapy produced highly significant propor-
tional reductions in the odds of death both for women under the
age of 50 years and for women aged 50–69 years. Reductions in
recurrence emerged chiefly during the first 5 years of follow-up,
whereas survival differences grew throughout the first 10 years.
An important finding was that the proportional reductions in risk
were similar for women with both node-negative and node-posi-
tive disease, although the absolute reduction was greater in node-
positive women with a higher absolute risk. The age-specific
benefits were largely irrespective of menopausal status at presen-
tation, oestrogen receptor status of the primary tumour and of
whether adjuvant tamoxifen had been given or not. There was also
the suggestion that anthracycline-containing regimens have
significantly greater benefits on recurrence and survival than more
traditional CMF schedules. Adjuvant trials with new agents
including the taxanes are currently underway, and preliminary data
from one such trial suggests a small but statistically significant
further survival gain for the use of paclitaxel following standard
adriamycin/cyclophosphamide chemotherapy.
These findings suggest that more women are likely to gain
from adjuvant chemotherapy than was previously realized, with
consequent implications for the resourcing and delivery of
chemotherapy services.
Preoperative chemotherapy is an important new approach to the
treatment of early breast cancer, using the primary tumour as an in
vivo measure of responsiveness to therapy. Current evidence from
randomized trials suggests that survival is very similar whether
such treatment is given before or after surgery, but the need for
mastectomy is reduced when chemotherapy is used preoperatively.
This approach requires the closest possible cooperation between
the oncologist and the surgeon working together with patients in
multidisciplinary clinics from the time of first-diagnosis. This in
turn has implications for the organization and staffing of breast
clinics.
Several new drugs, in particular paclitaxel, docetaxel and
vinorelbine, have been shown to be very active in the treatment of
metastatic breast carcinoma. For the first time, data from random-
ized trials using these drugs suggest a survival benefit over some
conventional schedules in patients with metastatic disease.
Evidence also exists indicating symptom-relief and quality-of-life
benefits. The key issue here concerns cost: some of these new
agents are much more expensive than conventional therapy.
Currently, ‘rationing’ of new therapies is determined by individual
authorities, leading to so-called ‘postal code prescribing’. A
national policy for determining cost-effectiveness of new
chemotherapies in patients with metastatic breast cancer is
urgently required.
Endocrine therapy – Anthony Howell (Christie Hospital,
Manchester, UK)
Endocrine treatment is the preferred first-line therapy for
advanced breast cancer because of its good tolerability. In addi-
tion, up to half of patients will respond again to endocrine therapy
second-line, and promising results have been obtained with
endocrine agents in third- and fourth-line treatment. Thus the aim
of endocrine therapy should be to achieve as great a response as
possible first-line. At present, tamoxifen is the drug of choice as
first-line endocrine therapy for metastatic breast cancer with no or
minimal symptoms in premenopausal or postmenopausal women.
New drugs such as second-and third-generation aromatase
inhibitors and new anti-oestrogens have recently been introduced
in the clinic or are in late development.
Apparent differences in the effectiveness of adjuvant therapies
according to age has led to controversy concerning the optimum
treatment for women with breast cancer above and below 50 years
of age. In all cases the treatment of choice for ER-positive patients
is tamoxifen. Ideally this should be given for a period of 5 years.
An overview of randomized trials using adjuvant tamoxifen in
women with early breast cancer confirmed that it is possible to
improve the 10-year survival of women with ER-positive tumours,
with proportional reductions in breast cancer recurrence and
mortality (EBCTCG 1998b).
Thus the appropriate use of endocrine therapies in breast cancer
depends on:
• Understanding the effect of endocrine therapies and the mech-
anisms of resistance associated with their use.
• Developing new agents with novel endocrine anti-tumour
effects.
• Defining the best way to combine endocrine agents with
cytotoxic or other endocrine agents.
• Identifying the long-term effects of endocrine agents in terms
of disease control and prevention, as well as desirable and
undesirable side-effects.
Endocrine therapy’s uses in advanced disease and adjuvant
therapy are well defined, and it must be offered. When endocrine
therapy is no longer effective then chemotherapy should be
considered with close consultation with the patient.
Advantages and disadvantages of a multidisciplinary
approach – Lesley Fallowfield (University College
Medical School, London, UK)
There are few data on the advantages and disadvantages of a
multidisciplinary team approach. Some of the putative advantages
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demonstrable lack of effective communication between specialists
and departments can cause confusion for the patients about diag-
nosis, test results and future management plans. In the speaker’s
experience, even in good teams, members tend to be unaware of
what other members are saying to patients. Too often, important
information for the patient is omitted on the assumption that
someone else must have relayed the relevant facts at appropriate
times. This can be confusing and cause a loss of confidence in the
team, provoking needless anxiety for the patients; it is also frus-
trating for clinicians who may have to spend extra time communi-
cating quite basic information to an unprepared or misinformed
patient.
A related issue concerns the benefits of rapid communication of
results of investigations. Data emerging from the very few studies
which have been conducted indicate that, particularly for one-stop
clinics, while anxiety is indeed reduced for those who have benign
disease, 1 day appears to be too rapid for those who have malig-
nant disease confirmed. Women with malignant disease fared
better where there was a 2–3 day delay between undergoing inves-
tigations and being informed of the results and treatment options.
It may be that time to consider the implications of malignancy is
beneficial to the patient’s adaptation.
Quality and quantity of information need to be distinguished –
more is not necessarily better. Theoretical improvements in
communication provided by a multidisciplinary team may well be
shown, but such approaches are alien to many health care profes-
sionals who have been educated within a hierarchical system.
Hardly any time is devoted, at any level of training of medical
personnel, to developing communication skills. Data from
communication-skills training courses for senior doctors in cancer
medicine and specialist chemotherapy nurses show that many find
communication with colleagues one of the most stressful and
unsatisfying aspects of their work. This may compound the stres-
sors common to any organizational unit: role-uncertainty, role-
ambiguity, role-conflict, role-overload, and so on. The vast
literature accumulated by occupational psychologists could be
brought to bear on these problems in the context of the multidisci-
plinary team. Unless old practices are abandoned, training
provided and different patterns of communication established,
then benefits to everyone in the system will not be realized.
Primary care – Ivan Cox (Laurie Pike Health Centre,
Birmingham, UK)
The reorganizations resulting from C–H are now impacting upon
primary care, and GPs are coming to terms with the ‘cancer
pathway’ model of care. The three areas in the management of
breast cancer patients where this impact is being felt most are:
• early recognition, diagnosis and referral
• prescribing during remission
• follow-up.
‘Fast tracking’ and the ‘2-week rule’ are having significant impli-
cations for GPs at both cultural and organizational levels. In partic-
ular, GPs are having to reconsider their own procedures in
differentiating between potentially malignant and non-malignant
breast lumps. This might lead to some GPs becoming ‘de-skilled’
in diagnosis, simply referring every suspicious patient. Further to
this, they have to become familiar with the entry criteria and
guidelines for admitting patients to the fast-track service. There is
some evidence (both anecdotal or from small studies) that, even
where local guidelines on how to get patients into fast-track
systems exist, only about 30–40% of GPs use them, preferring
instead to refer to a consultant familiar to them. By contrast, in
places where use of the fast-track system has taken off, some GPs
refer somewhat indiscriminately to the fast-track system. A small
telephone survey by the speaker of six specialist clinics in
Birmingham and Sandwell found that in some places the referral
rate to fast-track clinics has risen by up to 100% in 2 years;
concomitantly, in these units, the incidence of breast cancer
detected among patients so referred has fallen from about 1 in
10–11 to about 1 in 18–24.
There are grave misgivings in general practice about the 2-week
rule. Firstly, over its measurement. When does this period
commence? From the first presentation or at the point when the
referral is received by the specialists? There are some patients who
do not want to be fast-tracked; they may want time to consider
their position at each of the stages. The GP is also under pressure
to pick up the fall-out from an increased number of worried-well
patients resulting from fast-track clinics.
Further, with cash-limited prescribing budgets, some GPs are
unhappy at having to pick up long-term prescriptions for the anti-
oestrogens, particularly those in trials. The combined budgets to be
given primary care groups may see an end to this bickering.
Though the debate over the value of follow-up itself is intensi-
fying, patient pressure will undoubtedly force a significant amount
of follow-up on the system – if only in the short term. The shift in
resourcing to implement fast tracking is encouraging the specialist
breast services to offload follow-up care. GPs are divided over the
benefits of managing this in primary care. Again, resourcing is one
of the issues of major concern.
However, one important outcome of the recent RCGP Cancer
Care Workshops was the desire to work much more closely with
specialists on all of these issues. The creation of primary care
groups should encourage this further.
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